VNDA Vanda Pharmaceuticals Inc

Conference Call and Webcast to Follow ROCKVILLE, Md., April 24 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced it will release results for the first quarter ended March 31, 2008, on Thursday, May 1, 2008, before the market opens. A full text copy of the release will be disseminated at that time. Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference call to discuss the results and other corporate developments at 10:30 AM ET on Thursday, May 1, 2008. Also participating on the call will be Steven A. Shallcross, Senior Vice President and CFO. To participate in the conference call, dial the appropriate number below shortly before the 10:30 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos. The teleconference dial-in numbers are as follows: Domestic callers 1-866-510-0710 International callers 1-617-597-5378 The conference call will be broadcast simultaneously and archived on the company's Web site, http://www.vandapharma.com/. Investors should go to the Web site at least 15 minutes early to register, download, and install any necessary audio software. A replay of the call will be available on Thursday, May 1, 2008, beginning at 12:30 PM ET and will be accessible until Thursday, May 8, 2008, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 34135192. About Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates. Vanda's lead product candidate, Fanapta(TM) (iloperidone), is a compound for the treatment of schizophrenia and bipolar disorder, for which Vanda has submitted an NDA to the FDA. Vanda's second product candidate, tasimelteon (VEC-162), is a compound for the treatment of sleep and mood disorders, which is currently in Phase III for sleep disorders. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness in Phase II. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com/. DATASOURCE: Vanda Pharmaceuticals Inc. CONTACT: Steven A. Shallcross, Senior Vice President, Chief Financial Officer of Vanda Pharmaceuticals Inc., +1-240-599-4500 Web site: http://www.vandapharma.com/

Copyright